How does infliximab work in rheumatoid arthritis?
How does infliximab work in rheumatoid arthritis?
复制标题
DOI：
10.1186/ar549
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
Feldmann M
中科院分区：
文献类型：
--
作者：
Maini RN;Feldmann M
自从肿瘤坏死因子α（TNFα）的最初特性被发现以来，人们已经清楚TNFα具有多种生物活性。认识到TNFα在类风湿性关节炎（RA）中发挥作用，导致开发了用于治疗RA的抗TNF药物。英夫利西单抗是一种嵌合单克隆抗体，具有高亲和力，可特异性结合TNFα并中和细胞因子，目前已被批准用于治疗RA和克罗恩病（另一种免疫炎症性疾病）。除了确定英夫利西单抗的安全性和疗效外，临床研究还提供了RA病理生理学中涉及的复杂细胞和精氨酸依赖性途径的见解，包括支持TNFα参与细胞因子调节、细胞募集、血管生成和组织破坏的证据。
Since the initial characterization of tumor necrosis factor alpha (TNFα), it has become clear that TNFα has diverse biologic activity. The realization that TNFα plays a role in rheumatoid arthritis (RA) has led to the development of anti-TNF agents for the treatment of RA. Infliximab, a chimeric monoclonal antibody that specifically, and with high affinity, binds to TNFα and neutralizes the cytokine, is currently approved for the treatment of RA and Crohn's disease, another immune-inflammatory disorder. In addition to establishing the safety and efficacy of infliximab, clinical research has also provided insights into the complex cellular and cytokine-dependent pathways involved in the pathophysiology of RA, including evidence that supports TNFα involvement in cytokine regulation, cell recruitment, angiogenesis, and tissue destruction.